AN2 Therapeutics, Inc., (ANTX): Price and Financial Metrics
ANTX Price/Volume Stats
| Current price | $2.28 | 52-week high | $22.22 |
| Prev. close | $2.40 | 52-week low | $2.28 |
| Day low | $2.28 | Volume | 178,900 |
| Day high | $2.40 | Avg. volume | 396,885 |
| 50-day MA | $3.02 | Dividend yield | N/A |
| 200-day MA | $12.16 | Market Cap | 67.88M |
ANTX Stock Price Chart Interactive Chart >
AN2 Therapeutics, Inc., (ANTX) Company Bio
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Latest ANTX News From Around the Web
Below are the latest news stories about AN2 THERAPEUTICS INC that investors may wish to consider to help them evaluate ANTX as an investment opportunity.
One AN2 Therapeutics Insider Raised Their Stake In The Previous YearLooking at AN2 Therapeutics, Inc.'s ( NASDAQ:ANTX ) insider transactions over the last year, we can see that insiders... |
AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific HighlightsMENLO PARK, Calif., November 09, 2023--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended September 30, 2023. |
AN2 Therapeutics, Inc. (ANTX) Is a Great Choice for 'Trend' Investors, Here's WhyAN2 Therapeutics, Inc. (ANTX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. |
AN2 Therapeutics to Present at Upcoming Investor ConferencesMENLO PARK, Calif., November 06, 2023--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that company management will participate in two upcoming investor conferences in November. |
AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas DiseaseMENLO PARK, Calif., October 18, 2023--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that it has received an exclusive license from the University of Georgia Research Foundation to advance the development of a boron-containing small molecule for Chagas disease. These boron-based molecules were originally discovered by researchers at Anacor |
ANTX Price Returns
| 1-mo | -29.19% |
| 3-mo | -88.31% |
| 6-mo | -84.31% |
| 1-year | -71.46% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -88.87% |
| 2023 | 115.01% |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...